Vaccination against Meningitis: Details, Advantages, Risks, and Further Information
In the United States, the routine vaccination schedule for infants and children focuses on two vaccines to protect against meningitis: the meningococcal conjugate vaccine (MenACWY) and the serogroup B meningococcal vaccine (MenB).
For the MenACWY vaccine, the first dose is recommended at ages 11 to 12 years. A booster dose is recommended at age 16 years. If the first dose is given after age 16, a booster is not needed. Younger children, who may be at higher risk due to health conditions or outbreaks, can receive MenACWY as early as 8 weeks old.
The MenB vaccine is not routinely recommended for all healthy children but is advised for those aged 10 years or older who have increased risk factors. For healthy adolescents and young adults aged 16–23 years, MenB is typically administered as a 2-dose series. For those at increased risk aged 10 years or older, a 3-dose series is recommended.
Infants under 2 years may have a different dosing schedule depending on the vaccine product and their risk status. These recommendations were updated and adopted by the CDC in 2024 and reflected in the 2025 immunization schedule for children and adolescents. Pediatricians can provide guidance tailored to individual child health and risk factors.
It's important to note that infants and young children are especially at risk of meningitis, as their immune systems are not fully developed and able to fight off the disease. Bacterial meningitis, which is particularly dangerous, can lead to permanent disabilities, brain damage, or death.
Pneumococcal bacteria can cause meningitis and other serious infections like pneumonia. Viral meningitis is often less severe than bacterial meningitis and people with properly functioning immune systems usually recover on their own, while others may require medical attention. The MMR vaccine protects against measles, mumps, and rubella, which can cause viral meningitis and measles-related meningitis.
Since 2005, meningitis in certain groups of teenagers has decreased by over 90% due to MenACWY vaccinations. Before a vaccine became available, Haemophilus influenzae type b (Hib) was the leading cause of bacterial meningitis.
Both MenACWY and MenB vaccines are associated with mild problems that can last for 1-2 days for MenACWY and 3-5 days for MenB, including headache, fatigue, joint or muscle pain, and pain and flushing at the injection site. Most people who receive a meningitis vaccine do not experience any serious side effects, but serious reactions are possible. It is important to inform a child's doctor if they are experiencing any side effects related to the vaccine.
Vaccination is essential for the prevention of meningitis. Bacterial meningitis can be fatal, so it requires immediate medical attention. For more than 80% of children who die as a result of this type of meningitis, death occurs within 24 hours of diagnosis.
Herd immunity is unlikely to prevent meningitis, so it is essential that people get vaccinated and have their children vaccinated. The pneumococcal vaccine is initially administered at 2, 4, and 6 months of age, with a booster between 12 and 15 months, while the Hib vaccine is usually administered at the same ages.
It's also important to note that parasitic, fungal, and primary amebic meningitis are rare but can have severe consequences. Parasitic meningitis is not generally contagious and people usually contract it by eating infected animals or contaminated foods. Around 10% of affected children die, and some are left with lifelong disabilities. Fungal meningitis occurs through the inhalation of fungal spores and is usually treatable with antifungal medications. People with weakened immune systems are at higher risk. Primary amebic meningitis is a rare and damaging infection of the brain caused by a microscopic ameba called Naegleria fowleri, which lives in warm water and soil. It is not contagious and people usually contract it when swimming in water containing the ameba.
Meningitis is a condition that causes inflammation in the meninges, the membranous coverings that protect the brain and spinal cord. The most common meningococcal vaccine is the meningococcal conjugate vaccine, which is usually started at 11 years of age and has a booster at 16 years.
Vaccines, such as the meningococcal conjugate vaccine (MenACWY) and the serogroup B meningococcal vaccine (MenB), are essential tools in the science of health-and-wellness, particularly for the prevention of bacterial meningitis, a serious disease that can lead to permanent disabilities or even death. These vaccines follow a recommended schedule, with the first dose of MenACWY typically given at ages 11 to 12 years and a booster at age 16 years, while the MenB vaccine may be administered as a 2-dose series for healthy adolescents and young adults aged 16–23 years.
